期刊文献+

不同配比头孢噻肟/舒巴坦对180株临床分离菌的体外抗菌活性 被引量:5

Antibacterial Activities of Cefotaxime/sulbactam with Various Proportions against 180 Clinical Isolates in vitro
下载PDF
导出
摘要 目的:研究不同配比的头孢噻肟/舒巴坦及头孢噻肟单剂对临床分离菌体外抗菌作用。方法:采用平皿二倍稀释法测定头孢噻肟/舒巴坦对180株临床分离菌的最低抑菌浓度(MIC)、最低杀菌浓度(MBC)。结果:头孢噻肟/舒巴坦(1∶1,2∶1)对180株临床分离菌具有广谱抗菌作用,对革兰阴性杆菌MIC90为0.25~32 mg.L-1,是头孢噻肟单剂的1/4~1/8,明显强于头孢噻肟单方使用效果,同时也强于头孢噻肟/舒巴坦(4∶1,8∶1)。结论:1∶1及2∶1配比的头孢噻肟/舒巴坦对绝大多数临床感染细菌有很强的抗菌活性,明显优于头孢噻肟单剂和头孢噻肟/舒巴坦其他配比。 Objective: To study the in vitro antibacterial activities of cefotaxime and cefotaxime/sulbactam (CTX/SBT) with different proportions. Method : The minimal inhibitory concentrations (MIC) and the minimal bactericidal concentrations (MBC) were measured in 180 clinical isolates. Result: CTX/SBT with proportion of 1:1 and 2:1 both displayed potent and broad - spectrum antibacterial activities against 180 clinical isolates irt vitro, which were better than CTX and CTX/SBT with proportion of 4:1 and 8: 1. MIC90 of CTX/SBT ( 1 : 1 and 2:1 ) against gram-negative bacteria was 0.25 - 32 mg · L- 1, which was 1/4 - 1/8 of that of cefotaxime. Conclusion: CTX/SBT with proportion of 1:1 and 2:1 shows promising antibacterial activities against the major clinical isolates with better effect when compared with cefotaxime and cefotaxime/sulbactam with the other proportions.
出处 《中国药师》 CAS 2012年第8期1113-1116,共4页 China Pharmacist
关键词 头孢噻肟 舒巴坦 复方制剂 体外抗菌活性 Cefotaxime Sulbactam Compound preparation In vitro antibacterial activity
  • 相关文献

参考文献7

二级参考文献47

  • 1沈德莉,黄仲义,范瑛,孙惠丽,赵永红.抗菌药使用与金黄色葡萄球菌耐药率变化相关分析[J].药物流行病学杂志,2005,14(4):244-246. 被引量:9
  • 2牛犇,张淑华,杨光,包旭,贺英菊,包定元,岳琼.熊胆贝母止咳胶囊在小鼠体内外的抗菌作用[J].华西药学杂志,2007,22(2):157-159. 被引量:3
  • 3Coelho JM, Turton JF, Kaufmann ME, et al. Occurrence of earba- penem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England[J].J Clin Microbiol, 2006, 44 (10) : 3623 -3627.
  • 4Brown S, Amyes SG. The sequences of seven class D B-1actamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents[J]. Clin Microbiol Infect, 2005, 11 (4) : 326 - 329.
  • 5Chen CH, Young TG, Huang CC. Predictive biomarkers for drugresistant Acinetobacter baumannii isolates with bla TEM-1, AmpC- type bla and integrase 1 genotypes[ J]. J Microbiol Immunol Infect, 2006, 39 (5) : 372 - 379.
  • 6Endimiani A, Luzzaro F, Migliavacca R, et al. Spread in Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase[J]. Antimicrob Agents Chemother, 2007, 51 (6) : 2211 - 2214.
  • 7Naiemi NA, Duim B, Savelkoul PH, et al. Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology[ J]. J Clin Microbiel, 2005, 43(9) : 4862 -4864.
  • 8Nagano N, Nagano Y, Cordevant C, et al. Nosocomial transmission of CTX-M-2 beta-lactamase-producing Acinetobacter baumannii in a neurosurgery ward [ J ]. J Clin Microbiol, 2004, 42 (9) : 3978 -3984.
  • 9Tsakris A, Ikonomidis A, Pournaras S, et al. VIM-I Metallo-β- lactamase in Acinetobacter baumannii[ J]. Emerg Infect Dis, 2006, 12 (6) : 981 -983.
  • 10Jones RN, Biedenbach DJ, Sader HS, et al. Emerging epidemic of metallo-β-1actamase-mediated resistances [ J ]. Diagn Microbiol Infect Dis, 2005, 51(2) : 77 -84.

共引文献244

同被引文献35

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部